Dose Escalation Study With Bispecific Antibodies in Adult Patients With Lupus Nephritis

NCT06975787

Status	RECRUITING
Phase	Phase 1
Sponsor	Regeneron Pharmaceuticals
Enrollment	90 participants

Key Eligibility Criteria

Inclusion (2)

- Diagnosis of Systemic Lupus Erythematosus (SLE) and LN, as described in the protocol
- Participant must have refractory or relapsed disease, as described in the protocol

Exclusion (3)

- History of or active severe or unstable lupus-associated neuropsychiatric disease that is likely to require acute or emergent medical treatment or hospitalization
- Active overlap syndrome with mixed connective tissue disease or systemic sclerosis within 12 months prior to screening or during screening
- Catastrophic or severe antiphospholipid syndrome within 12 months prior to screening or during screening

Locations (6 total)

Mayo Clinic, Rochester, Minnesota, United States
University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany
Seoul National University Hospital, Seoul, South Korea
... and 3 more locations